番茄社区

Charles Bankhead

Charles Bankhead

Authors >

Charles Bankhead

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. His career spans more than 30 years, including a decade with Medical World News, a leading medical trade magazine of its time. He had a long and successful freelance career before joining 番茄社区 in 2007. Charles graduated with honors from Texas Tech University, receiving a BA in journalism, and completed a master's degree in mass communication, with specialization in health communication, also at Texas Tech.

Connect:

email image

Latest from Charles Bankhead

Onco Break over a computer rendering of a cancer cell.

Advances in TNBC; Mixed News in Lung Cancer Report; Pancreatic Cancer Overdiagnosis?

News, features, and commentary about cancer-related issues

A photo of a woman receiving chemotherapy.

Small Benefit, Persistent Toxic Risk With Adjuvant Anthracycline in Breast Cancer

Time for "long goodbye" to the "burning red devil," say editorialists

FDA APPROVED revumenib (Revuforj) over a computer rendering of leukemia cells.

FDA Approves First Menin Inhibitor for Acute Leukemia

Complete responses in 21% of patients treated with single-agent revumenib

A close up photo of a neurofibroma.

MEK Inhibitor Scores Big Win in Adults, Children With Neurofibromatosis Type 1

More than 40% of adults, half of children met response criteria, majority of responses durable

Onco Break over a computer rendering of a cancer cell.

Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer

News, features, and commentary about cancer-related issues

IKCS over a photo of Omni Louisville in Louisville, KY.

Targeted Combination Shows Promise in Metastatic Kidney Cancer

Other IKCS news: closer look at belzutifan safety, challenges of triplet therapies for RCC

IKCS over a photo of Omni Louisville in Louisville, KY.

Large, Grade 4 Kidney Tumors Pose Risk of Early Cancer-Specific Mortality

Possible guidance for use of adjuvant immunotherapy in high-risk, non-metastatic disease

IKCS over a photo of Omni Louisville in Louisville, KY.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

Better OS, PFS, response rate, but newer combination strategies not included

IKCS over a photo of Omni Louisville in Louisville, KY.

Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control

More IKCS news: Long-term survival benefit with nivolumab/ipilimumab, disease-slowing surgery

IKCS over a photo of Omni Louisville in Louisville, KY.

Higher Risk of Kidney Cancer Recurrence After Ablative Therapy

Low rate of recurrence with surgery or nonsurgical options, but data can inform decisions

1

鈥�